Novadip Biosciences Secures $50M Series C Funding to Accelerate Breakthroughs in Regenerative Healing

Novadip Biosciences S.A. is thrilled to announce that we have raised €50,000,000 in our latest funding round, marking a significant milestone in our mission to innovate regenerative medicine. As a clinical-stage biopharmaceutical company, Novadip is committed to designing, developing, and bringing groundbreaking regenerative tissue products to market that accelerate healing for patients dealing with large bone defects and severe injuries. This funding injection is a testament to the confidence our investors have in our pioneering technology and its potential to revolutionize treatment approaches. Our lead product, NVD-X3, is an allogeneic, “off-the-shelf” solution that utilizes a matrix enriched with multiple bioactive factors, enabling accelerated tissue healing while offering superior intraoperative handling characteristics. With its ability to be shipped and stored at room temperature, NVD-X3 is poised to become a game changer in the orthopedic sector, offering surgeons a much-needed solution for immediate intervention. Additionally, we are advancing our clinical development programs with NVD-003, an autologous therapy derived from ASCs aimed at treating congenital pseudarthrosis of the tibia (CPT)—a rare and challenging pediatric bone condition. The funds raised will predominantly be used to propel further clinical trials, refine our manufacturing processes, and expand our research initiatives, ultimately bringing both NVD-X3 and NVD-003 closer to regulatory approval and clinical use. As we continue to innovate at the intersection of biotechnology and regenerative medicine, we remain dedicated to enhancing patient outcomes and restoring mobility for those in need. To learn more about our technology platform and clinical development programs, visit www.novadip.com or contact us at +32/10 77 92 20 and info@novadip.com.